Amprion
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10355 Science Center Dr Ste 240, San Die...Phone Number
(858) 461-6338Website
www.ampriondx.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Amprion
Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprions intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-SYN biomarker test (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies associated with Parkinsons disease, Lewy body dementia, and Alzheimers disease with Lewy body copathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies.Explore more
Amprion Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amprion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Amprion has new funding data
Check if Amprion has recently received funding, and reach out quickly before it becomes old news!
Check out if Amprion is spiking on competitors!
Click to see if Amprion had a recent Job posting/layoffs
Product Launch: Get notified when Amprion launches new products
Website visits: Recent activity has been detected on your website
Amprion, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Amprion recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Amprion
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Amprion
Find 3 more new buyers
Company Profile Activity
Activity Insights
Amprion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Amprion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Amprion.
Amprion financials insights
Gather financial insights about Amprion, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series B
$15M
Amprion Tech Stack
A closer look at the technologies used by Amprion
Amprion News & Media
Amprion Honored to Win the 2024 BioTech Breakthrough Award ‘Clinical Diagnostics Solution of the Year’
SAN DIEGO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnoses of neurodegenerative disorders, is closing out 2024 with several prestigious awards. Its novel assay, SAAmplify™-ɑSYN, won ‘Clinical Diagnostics Solution of the Year’ through the Biotech Breakthrough Awards Program. The Michael J. Fox Foundation (MJFF) also awarded Amprion’s co-founder, Dr. Claudio Soto, with ‘The Robert A. Pritzker Prize for Leadership in Parkinson's Research.’ Amprion’s SAAmplify-ɑSYN (formerly SYNTap®)
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amprion
Sign Up For FreeTo access detailed company insights
Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprions intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-SYN biomarker test (formerly SYNTap®) is the only seed amplification assay available to aid the diagnos... Read More
